Compare Arko Corp. (ARKO) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Arko Corp. vs Pfizer Inc — how do they compare? Arko Corp. trades at $4.46 (market cap $527.27M), while Pfizer Inc trades at $26.61 (market cap $154.18B). The key difference: Pfizer Inc is far larger — about 292.4× Arko Corp.'s market cap, and Pfizer Inc pays the higher dividend (6.36%). Which is the better fit depends on your goals.
| ARKO | PFE | |
|---|---|---|
Market Cap | $527.27M | $154.18B |
Sector | Consumer Cyclical | Health |
52-Week High | $8.64 | $28.56 |
52-Week Low | $3.82 | $23.60 |
Enterprise Value | $2.71B | $205.67B |
Dividend Yield | 2.55% | 6.36% |
Volume | — | 29,869,932 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKO Corp. (NASDAQ: ARKO) trades at $5.66, down 22.36% following weak Q2 2026 earnings that missed expectations. The stock shows bearish technical signals with oversold RSI readings near support at $5. Despite revenue declining to $7.64B in 2025, the company maintains positive cash flow and recently paid a $0.03 dividend. Analyst consensus remains cautious with 100% hold ratings amid concerns about consumer spending pressures.
The outlook remains challenging with declining revenues and thin profit margins (0.38% net margin), though management maintains 2026 EBITDA guidance. Key risks include competitive pressure in convenience retail and sensitivity to fuel price volatility. The current valuation at 0.08 P/S ratio may attract value investors if operational improvements materialize.
Pfizer (PFE) trades at $26.62, down 0.45% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. The company reported three consecutive quarterly earnings beats in 2026, with Q3 2026 EPS expected at $0.79. Revenue for 2025 was $62.58 billion, with a net income margin of 12.41%, though 2026 projections show a decline to 6.8%. Positive news highlights pipeline advancements in obesity and oncology therapies.
Pfizer presents a mixed outlook: bullish technicals and analyst support contrast with declining profit margins and patent cliff risks. Investment opportunities include a solid dividend yield and catalyst-rich pipeline in 2026, but risks involve revenue volatility post-COVID and competitive pressures. The stock's current valuation at a P/E of 35.59 may limit near-term upside absent earnings acceleration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Arko Corp.
ARKO Corp operates as a holding company. The company, through its subsidiaries, owns and operates convenience stores in the United States. Some of its regional store brands include Stop, Admiral, Apple Market, BreadBox, E-Z Mart, fas mart, Li'l Cricket, and Next Door Store. Its retail store offers hot food service, beverages, cigarettes & other tobacco products, candy, salty snacks, grocery, beer, and general merchandise. ARKO operates in three segments: Retail, Wholesale, and GPM Petroleum. The company derives the majority of its revenue from retail and wholesale distribution of fuel.
Read more on ARKO →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
